HIF1A and colorectal carcinoma: To approach this, Xu et al. (2019) encapsulated the HIF-1 inhibitor, acriflavine (ACF), and Dox into L (Dox-ACF@L) and constructed bifunctional L. The chemotherapeutic efficiency of Dox-ACF@L at various concentrations was tested in murine colorectal carcinoma (CT26) cells, and the results revealed improved tumor cell inhibition with the HIF-1 inhibitor.